Artificial intelligence has crossed a threshold in the pharmaceutical industry, according to a new report covered this week by Indian news outlets: it is no longer a side experiment run by innovation teams, but core infrastructure inside drug research and development.
The reporting, carried by ANI (aninews.in) and syndicated through outlets including MSN and webindia123, describes AI as "rapidly becoming a core part of pharmaceutical research and development," moving beyond its role as an experimental technology. The underlying research is credited to a report by Prezent Vivo.
According to the coverage of that report, AI is now treated as a core capability rather than a pilot project, and is being used to accelerate the drug discovery process, improve research productivity, and guide scientific decisions inside pharmaceutical companies.
That framing — infrastructure rather than experiment — is the substance of the story. An experimental tool is something a company can switch off after a disappointing quarter. Infrastructure is something the rest of the operation gets built on top of: budgets, hiring, data pipelines, and the way scientists decide which molecules are worth chasing in the first place.
The reports do not, in the coverage available, put figures on how much time or money AI is saving, name specific drug programs, or detail which techniques are involved. What they assert is a shift in status.
Why it matters: drug discovery is famously slow and expensive, and if AI is genuinely becoming standard equipment rather than a showcase project, it changes how quickly new medicines can move from idea to trial — and which companies can afford to compete.